Description

Wilson’s disease is a rare autosomal recessive disorder of copper metabolism which is characterised by hepatic and neurological disease

This episode of EASL Studio will:

• Cover the difficulties in diagnosing Wilson’s disease.
• Discuss treatment options and strategies.
• Explore the challenges faced by patients with Wilson’s disease.

Faculty

• Prof. Emmanuel Tsochatzis (Moderator)
• Dr Wiebke Papenthin (Patient Perspective)
• Dr Aurélia Poujois (Faculty)
• Prof. Piotr Socha (Faculty)

Related episodes:

• S4E7 – Genetics in adult liver disease – missed opportunities?
• S3E10 – Cholestatic pruritus: Can the itch be ditched?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

The EASL Policy Statement on liver cancer screening has recently been updated.

In addition to addressing the updates, this episode of EASL Studio will discuss how risk-based surveillance of hepatocellular carcinoma (HCC) in patients suffering from cirrhosis is a cost effective strategy to increase benefits, reduce the harm of HCC surveillance.

Faculty

• Prof. Thomas Berg (Moderator)
• Mr. Pietro Fiocchi (Faculty)
• Prof. Peter Jepsen (Faculty)
• Mrs. José Willemse (Patient Perspective) 

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Through widespread multidisciplinary collaboration, consortia and EU grants provide unique opportunities to address critical questions.

• What opportunities exist for early career scientist?
• Which elements are essential for success?
• How have these partnerships contributed to advancements in the field?

Watch this episode of EASL Studio to find out.

Faculty

• Prof. Thomas Berg (Moderator)
• Prof. Rajiv Jalan (Moderator)
• Prof. Minneke Coenraad (Faculty)
• Dr Cornelius Engelmann (Faculty)
• Prof. Pierre-Emmanuel Rautou (Faculty)

Related episode

• S4E2 YI Choice: How to build consortia and registries

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Emerging therapeutics based on gene addition, editing, or silencing are expected to change the landscape of genetic liver disease.

Watch this episode to find out:

• Which approaches exist?
• Where are they in terms of preclinical and clinical development?
• How will they be used?

Faculty

• Dr Mattias Mandorfer (Moderator)
• Dr Gloria Gonzalez-Aseguinolaza (Faculty)
• Prof. Pavel Strnad (Faculty)
• Prof. Man-Fung Yuen (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.